Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
about
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitroNovel therapeutic strategies targeting HIV integraseEffect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS MethodCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Drug interactions and antiretroviral drug monitoring.Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesClinically relevant drug-drug interactions between antiretrovirals and antifungalsLack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Potential benefit of dolutegravir once daily: efficacy and safety.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceInvestigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceAntiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Biotransformation of Cobicistat: Metabolic Pathways and EnzymesPharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.Elvitegravir: a once-daily inhibitor of HIV-1 integrase.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Pharmacology of HIV integrase inhibitors.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.HIV Drug Resistance and the Advent of Integrase Inhibitors.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.The preclinical discovery and development of dolutegravir for the treatment of HIV.Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response.Rifabutin: where do we stand in 2016?Renal effects of novel antiretroviral drugs.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Elvitegravir for the treatment of HIV.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.Adipose Tissue in HIV Infection.Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.Viral kinetics in semen with different antiretroviral families in treatment-naïve HIV-infected patients: a randomized trial.Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.Elvitegravir concentrations in seminal plasma in HIV-1-infected men.Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.Divalent metals and pH alter raltegravir disposition in vitro.
P2860
Q24633870-7A61C998-5CE4-472E-9CA6-D2AD0CECD026Q27003960-AFDD3939-B2D6-407B-8E05-59F6DBAB09E0Q28550189-7095C304-6259-4884-875A-23DAA8DAA7D6Q33680234-FCC07849-0E42-4A0E-8003-CE8D1E8EDB5CQ33686465-02ED8A49-D615-41AB-BE90-E7FCC27C9030Q34021173-14EACA69-725A-44EA-800C-EC128ABE079FQ34634156-72A03D69-6BCD-44D3-B2E1-3176528ED017Q35432739-F3157103-9B32-461C-862F-5A46CE77DE8BQ35892563-4B715C3E-E67A-4CF5-8BDB-2692379839C1Q36284159-16C5D696-FC65-4ED2-B774-732D621E173AQ36603416-2966C4B7-F8CC-4325-B9B9-72C1E02B63D4Q37288671-7B558962-D1ED-434A-85BA-AACB9A5A8F60Q37335799-87150733-BA95-4F67-A1E0-05CBDCE308EAQ37378110-04EF5222-65C9-4181-9A55-DF64053905B9Q37696729-2E039B7F-0EA2-4C6C-B9BD-B4E0260461A8Q37713076-0472AEF1-CD4B-4B20-8714-E015C42AF5BEQ37982825-AE192622-5592-4E58-A83E-E3C05B69950FQ38009758-A01158C4-5D64-4EA5-843C-C072A1BEC77CQ38025835-38F99C91-93F4-4852-88F3-03C533C1D1ECQ38030981-D54947C0-F3BF-4FAB-98AA-3C638232CD44Q38062462-1A068FD3-E93D-4511-A273-9373889917CCQ38109095-F2E11649-F9D0-4C14-93B1-D229E17EAE25Q38171345-BBA1426A-58A0-4869-AB45-CDB3CF7E3553Q38620489-DFF6A5D9-B004-4005-98AD-A388E06906DBQ38634561-A22C6DE3-B7A0-4D01-8E42-C057E6CD4283Q38786540-BFEE51EE-7AB4-45DF-B122-B3B571A88DA8Q38837077-5D1E5D13-F277-4667-95F9-6F3D315FEC45Q38882614-A8C582E5-8D00-4E84-AC86-83A56BED08DCQ38987327-ED0EF34A-5D82-45C2-8C98-DD2ED6998668Q39002230-338D5495-FC8D-4ADD-A066-1D5604A04CB2Q39064765-B8F78F09-1121-41C9-996B-EAFF7EAC97DAQ39118603-9080D85A-54DF-426A-8692-23749C0603D8Q40038736-88500395-E9F3-45ED-BDFD-0CCD4EDF7103Q40185119-391B2CB8-4A58-44B4-8CA3-EE9A85C1EC67Q40199953-B0A2F7F4-C525-4D68-A294-7ECF1C8B6383Q40225129-68F75966-4DAB-4C2B-A478-C0EAD8B7CD08Q40452205-95D91FB4-0424-407A-AB55-461118A3FF2EQ40593858-4610D34F-5A6D-4789-804C-C23DA3080428Q40735151-A5D8AB14-575D-41C7-B29A-49ADAA66BD9CQ42189797-DF109365-0BA9-44DD-88A3-B313D02E530F
P2860
Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@en
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@nl
type
label
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@en
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@nl
prefLabel
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@en
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@nl
P2093
P2860
P1476
Clinical pharmacokinetic and p ...... egrase inhibitor elvitegravir.
@en
P2093
Anita A Mathias
Brian P Kearney
Polina German
Srinivasan Ramanathan
P2860
P304
P356
10.2165/11584570-000000000-00000
P577
2011-04-01T00:00:00Z
P6179
1029943496